Effect of the Rho Kinase inhibitor Y-27632 on corneal endothelial wound healing

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 10, 2015, Pages 6067-6074

  Okumura, Naoki ^a,b   Inoue, Ryota ^a   Okazaki, Yugo ^a   Nakano, Shinichiro ^a   Nakagawa, Hiroko ^b   Kinoshita, Shigeru ^b   Koizumi, Noriko ^a  

^a DOSHISHA UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Bullous keratopathy; Corneal endothelial cells; PBK; ROCK inhibitor

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; KI 67 ANTIGEN; NERVE CELL ADHESION MOLECULE; PHALLOIDIN; RHO KINASE; RHO KINASE INHIBITOR; AMIDE; ENZYME INHIBITOR; PYRIDINE DERIVATIVE;

AGED; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASE REPORT; CATARACT EXTRACTION; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA EDEMA; CORNEA ENDOTHELIUM; CORNEAL ENDOTHELIAL CELL LOSS; DESCEMET MEMBRANE; DRUG DOSE REDUCTION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KERATOPATHY; MALE; NONHUMAN; PHACOEMULSIFICATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SLIT LAMP; VERY ELDERLY; VISUAL ACUITY; WOUND HEALING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CORNEAL INJURIES; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; INJURIES; PATHOLOGY; PILOT STUDY;

AMIDES; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CORNEAL INJURIES; DISEASE MODELS, ANIMAL; ENDOTHELIUM, CORNEAL; ENZYME INHIBITORS; HUMANS; PILOT PROJECTS; PYRIDINES; RABBITS; RHO-ASSOCIATED KINASES; WOUND HEALING;

EID: 84942097837     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-17595     Document Type: Article

References (47)

1. Ghosheh FR, Cremona FA, Rapuano CJ, et al. Trends in penetrating keratoplasty in the United States 1980-2005. Int Ophthalmol. 2008;28:147–153.
2. Eye Bank Association of America. 2013 Eye Banking Statistical Report. Washington, DC; Eye Bank Association of America; 2013.
3. Al-Yousuf N, Mavrikakis I, Mavrikakis E, Daya SM. Penetrating keratoplasty: indications over a 10 year period. Br J Ophthalmol. 2004;88:998–1001.
4. Keenan TD, Jones MN, Rushton S, et al. Trends in the indications for corneal graft surgery in the United Kingdom: 1999 through 2009. Arch Ophthalmol. 2012;130:621–628.
5. Cunningham WJ, Brookes NH, Twohill HC, et al. Trends in the distribution of donor corneal tissue and indications for corneal transplantation: the New Zealand National Eye Bank Study 2000-2009. Clin Exp Ophthalmol. 2012;40:141–147.
6. Tan DT, Janardhanan P, Zhou H, et al. Penetrating keratoplasty in Asian eyes: the Singapore Corneal Transplant Study. Ophthalmology. 2008;115:975–982.
7. Shimazaki J, Amano S, Uno T, Maeda N, Yokoi N. National survey on bullous keratopathy in Japan. Cornea. 2007;26:274–278.
8. Dandona L, Naduvilath TJ, Janarthanan M, Ragu K, Rao GN. Survival analysis and visual outcome in a large series of corneal transplants in India. Br J Ophthalmol. 1997;81:726–731.
9. Joyce NC. Proliferative capacity of the corneal endothelium. Prog Retin Eye Res. 2003;22:359–389.
10. Tan DT, Dart JK, Holland EJ, Kinoshita S. Corneal transplantation. Lancet. 2012;379:1749–1761.
11. Okumura N, Ueno M, Koizumi N, et al. Enhancement on primate corneal endothelial cell survival in vitro by a ROCK inhibitor. Invest Ophthalmol Vis Sci. 2009;50:3680–3687.
12. Okumura N, Koizumi N, Ueno M, et al. Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops. Br J Ophthalmol. 2011;95:1006–1009.
13. Okumura N, Koizumi N, Kay EP, et al. The ROCK inhibitor eye drop accelerates corneal endothelium wound healing. Invest Ophthalmol Vis Sci. 2013;54:2493–2502.
14. Koizumi N, Okumura N, Ueno M, Nakagawa H, Hamuro J, Kinoshita S. Rho-associated kinase inhibitor eye drop treatment as a possible medical treatment for Fuchs corneal dystrophy. Cornea. 2013;32:1167–1170.
15. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4:446–456.
16. Sebbagh M, Renvoize C, Hamelin J, Riche N, Bertoglio J, Breard J. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol. 2001;3:346–352.
17. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. Membrane blebbing during apoptosis results from caspasemediated activation of ROCK I. Nat Cell Biol. 2001;3:339–345.
18. Blumenstein L, Ahmadian MR. Models of the cooperative mechanism for Rho effector recognition: implications for RhoA-mediated effector activation. J Biol Chem. 2004;279: 53419–53426.
19. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007;50:17–24.
20. Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 2008;20:242–248.
21. Suzuki Y, Shibuya M, Satoh S, Sugimoto Y, Takakura K. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg Neurol. 2007;68: 126–131.
22. Garnock-Jones KP. Ripasudil: first global approval. Drugs. 2014;74:2211–2215.
23. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 1995;269:1270–1272.
24. Okumura N, Nakano S, Kay EP, et al. Involvement of cyclin D and p27 in cell proliferation mediated by ROCK inhibitors Y-27632 and Y-39983 during corneal endothelium wound healing. Invest Ophthalmol Vis Sci. 2014;55:318–329.
25. Pipparelli A, Arsenijevic Y, Thuret G, Gain P, Nicolas M, Majo F. ROCK inhibitor enhances adhesion and wound healing of human corneal endothelial cells. PLoS One. 2013;8:e62095.
26. Peh GS, Adnan K, George BL, et al. The effects of Rhoassociated kinase inhibitor Y-27632 on primary human corneal endothelial cells propagated using a dual media approach. Sci Rep. 2015;5:9167.
27. Gundersen T. Conjunctival flaps in the treatment of corneal disease with reference to a new technique of application. Arch Ophthalmol. 1958;60:880–888.
28. Rosa N, Cennamo G. Phototherapeutic keratectomy for relief of pain in patients with pseudophakic corneal edema. J Refract Surg. 2002;18:276–279.
29. Arora R, Manudhane A, Saran RK, Goyal J, Goyal G, Gupta D. Role of corneal collagen cross-linking in pseudophakic bullous keratopathy: a clinicopathological study. Ophthalmology. 2013;120:2413–2418.
30. Takahashi GH, Leibowitz HM. Hydrophilic contact lenses in corneal disease. 3. Topical hypertonic saline therapy in bullous keratopathy. Arch Ophthalmol. 1971;86:133–137.
31. Insler MS, Benefield DW, Ross EV. Topical hyperosmolar solutions in the reduction of corneal edema. CLAO J. 1987; 13:149–151.
32. Hoppenreijs VP, Pels E, Vrensen GF, Oosting J, Treffers WF. Effects of human epidermal growth factor on endothelial wound healing of human corneas. Invest Ophthalmol Vis Sci. 1992;33:1946–1957.
33. Hoppenreijs VP, Pels E, Vrensen GF, Treffers WF. Effects of platelet-derived growth factor on endothelial wound healing of human corneas. Invest Ophthalmol Vis Sci. 1994;35:150–161.
34. Lu J, Lu Z, Reinach P, et al. TGF-beta2 inhibits AKT activation and FGF-2-induced corneal endothelial cell proliferation. Exp. Cell Res. 2006;312:3631–3640.
35. Nakano Y, Oyamada M, Dai P, Nakagami T, Kinoshita S, Takamatsu T. Connexin43 knockdown accelerates wound healing but inhibits mesenchymal transition after corneal endothelial injury in vivo. Invest Ophthalmol Vis Sci. 2008;49: 93–104.
36. Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137–144.
37. Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48:3216–3222.
38. Tokushige H, Waki M, Takayama Y, Tanihara H. Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats. Curr Eye Res. 2011;36:964–970.
39. Williams RD, Novack GD, van Haarlem T, Kopczynski C; Group ARPAS. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011;152:834–841.
40. Tanihara H, Inoue T, Yamamoto T, et al. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131:1288–1295.
41. Tanihara H, Inoue T, Yamamoto T, et al. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156:731–736.
42. Van de Velde S, Van Bergen T, Sijnave D, et al. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014;55: 1006–1016.
43. Tanihara H, Inoue T, Yamamoto T, et al. Intra-ocular pressurelowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93:e254–260.
44. Tanihara H, Inoue T, Yamamoto T, et al. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol. 2015;133:755–761.
45. Powe NR, Schein OD, Gieser SC, et al. Synthesis of the literature on visual acuity and complications following cataract extraction with intraocular lens implantation. Cataract Patient Outcome Research Team. Arch Ophthalmol. 1994;112:239–252.
46. Van den Bruel A, Gailly J, Devriese S, Welton NJ, Shortt AJ, Vrijens F. The protective effect of ophthalmic viscoelastic devices on endothelial cell loss during cataract surgery: a meta-analysis using mixed treatment comparisons. Br J Ophthalmol. 2011;95:5–10.
47. World Health Organization. Global data on visual impairments. 2010;1–12.